Bionik Laboratories Corp. BNKL
OTC PK
| 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | 03/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 41.72% | -3.22% | -28.44% | -47.39% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 41.72% | -3.22% | -28.44% | -47.39% | -- |
| Cost of Revenue | 154.46% | 61.07% | 7.00% | -21.45% | -- |
| Gross Profit | 3.84% | -24.88% | -38.80% | -54.29% | -- |
| SG&A Expenses | 2.80% | 3.41% | 2.65% | -4.01% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.80% | 9.20% | 7.91% | -6.30% | -- |
| Operating Income | -0.01% | -13.63% | -20.39% | -6.91% | -- |
| Income Before Tax | 52.48% | 45.62% | 4.29% | 5.99% | -- |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 52.48% | 45.62% | 4.29% | 5.99% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 52.48% | 45.62% | 4.29% | 5.99% | -- |
| EBIT | -0.01% | -13.63% | -20.39% | -6.91% | -- |
| EBITDA | -0.85% | -16.62% | -23.49% | -9.08% | -- |
| EPS Basic | 59.53% | 51.61% | 17.98% | 19.29% | -- |
| Normalized Basic EPS | 27.42% | 8.32% | -3.11% | 2.75% | -- |
| EPS Diluted | 59.53% | 51.61% | 17.98% | 19.29% | -- |
| Normalized Diluted EPS | 27.42% | 8.32% | -3.11% | 2.75% | -- |
| Average Basic Shares Outstanding | 18.45% | 17.25% | 16.95% | 16.14% | -- |
| Average Diluted Shares Outstanding | 18.45% | 17.25% | 16.95% | 16.14% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |